Taken together, the experimental data allowed us to conclude that, whereas the highly aggressive TS/A cell line was only partially sensitive to Rnaset2-mediated tumor suppression (which was observed by in vivo assays only), the less tumorigenic C51 cell line turned out to undergo a marked Rnaset2-mediated tumor suppression in both in vitro and in vivo experimental settings, and was therefore chosen for further investigation. The gene discussed is RNASET2; the disease is neoplasm.